Zacks Research Issues Optimistic Forecast for EW Earnings

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Zacks Research raised their Q3 2025 earnings estimates for shares of Edwards Lifesciences in a research report issued to clients and investors on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $0.61 per share for the quarter, up from their prior estimate of $0.60. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences' Q4 2025 earnings at $0.63 EPS, Q2 2026 earnings at $0.66 EPS, Q3 2026 earnings at $0.70 EPS and FY2026 earnings at $2.75 EPS.

A number of other research firms also recently weighed in on EW. The Goldman Sachs Group boosted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, December 5th. UBS Group dropped their target price on Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating for the company in a research report on Tuesday, September 10th. Royal Bank of Canada boosted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a research report on Thursday, December 5th. Daiwa America downgraded Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 30th. Finally, Evercore ISI dropped their target price on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $78.65.

Edwards Lifesciences Price Performance

Shares of EW traded down $0.61 during trading hours on Friday, reaching $73.36. 1,509,813 shares of the company's stock traded hands, compared to its average volume of 4,636,094. The stock has a market cap of $43.27 billion, a PE ratio of 10.67, a price-to-earnings-growth ratio of 3.63 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm's 50 day simple moving average is $69.26 and its 200-day simple moving average is $74.19. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.57 billion. During the same period in the previous year, the business posted $0.59 EPS. The business's revenue for the quarter was up 8.9% compared to the same quarter last year.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently made changes to their positions in the stock. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC raised its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Peoples Bank KS acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $40,000. Finally, JFS Wealth Advisors LLC raised its stake in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after purchasing an additional 166 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,000 shares of company stock valued at $2,323,150 over the last 90 days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.